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Abstract
Background Meta-analyses suggest that schizophrenia pa-
tients with a history of cannabis use have less impaired cog-
nitive functioning compared to patients without cannabis use.
Aims The objective of this study was to assess the associa-
tion between recency and frequency of cannabis use and
cognitive functioning in at-risk mental state for psychosis
(ARMS) and first episode psychosis (FEP) individuals.
Methods One hundred thirty-six participants completed a
cognitive test battery and were assessed for current and past
cannabis use. Analyses of covariance models were applied to
evaluate the main effects of cannabis use and patient group
(ARMS vs. FEP) as well as their interactions on cognitive
functioning.
Results No differences were observed in cognitive perfor-
mance between current, former, and never users, and there
were no significant interactions between cannabis use and
patient group. Furthermore, within the group of current can-
nabis users, the frequency of cannabis use was not signifi-
cantly associated with cognitive functioning.
Conclusion The results of the present study do not support
the notion that FEP patients and ARMS individuals with a
history of cannabis use have less impaired cognitive func-
tioning compared to those without cannabis use.
Keywords First episode psychosis (FEP) . At-risk mental
state (ARMS) . Cannabis . Cognition . Schizophrenic
psychosis
Introduction
While the cognitively impairing effects of cannabis during
acute intoxication have been acknowledged for some time,
evidence has been accumulating in recent years that cannabis
may also cause subtle neuropsychological impairments that
persist beyond acute intoxication (Solowij and Pesa 2010).
Recent studies have shown that long-term, heavy cannabis
use can lead to cognitive deficits in a wide range of domains,
including memory, attention, inhibitory control, executive
functions, and decision making, and that these deficits are
still present after 1 week (Meier et al. 2012) and 1 month
(Bolla et al. 2005; Medina et al. 2007) of abstinence.
Furthermore, an increasing number of studies indicate that
the magnitude and persistence of cognitive impairment is
positively associated with the frequency and duration of use
and negatively associated with the age of onset of heavy
cannabis use (Solowij and Pesa 2010; Meier et al. 2012).
It has been suggested that the cognitive impairments
observed in healthy cannabis users are similar to those re-
ported in patients suffering from schizophrenic psychoses
(Solowij and Michie 2007). Neuropsychological impairment
is recognized as a core feature of schizophrenia (Palmer et al.
2009) and is not only present in patients with schizophrenic
psychoses, but already in individuals with an at-risk mental
state (ARMS) for psychosis (Brewer et al. 2006; Pflueger
et al. 2007; Riecher-Rössler et al. 2009; Giuliano et al. 2012).
Furthermore, it has been reported that ARMS individuals
with later transition to psychosis perform worse on tests
measuring verbal fluency, memory (Fusar-Poli et al.
2012; Van der Meer 2012), as well as speed of infor-
mation processing (Brewer et al. 2005; Riecher-Rössler
et al. 2009) than those without transition. Accordingly,
it has been demonstrated that prediction of psychosis
can be improved by taking neurocognitive performance
measures into account (Riecher-Rössler et al. 2009;
Koutsouleris et al. 2012).
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Given that cognitive impairments are frequently present in
patients with schizophrenia and healthy, heavy cannabis users
and given that brain structural changes have been observed in
cannabis-using schizophrenia patients particularly in cannabi-
noid receptor-rich regions (Rapp et al. 2012), wewould expect
cannabis-using schizophrenia patients to demonstrate particu-
larly severe neurocognitive deficits. Surprisingly, however,
the four most recent meta-analyses all demonstrated that
schizophrenia patients with a history of cannabis use have
less impaired cognitive functioning compared with non-using
schizophrenia patients (Potvin et al. 2008; Loberg and
Hugdahl 2009; Yucel et al. 2010; Rabin et al. 2011).
Two main hypotheses have been put forward to explain
these unexpected findings. Firstly, it has been proposed that
cannabis-using schizophrenia patients may belong to a sub-
group with better premorbid functioning and lower vulnera-
bility to psychosis and that, therefore, many patients in this
subgroup only transitioned to psychosis due to early initia-
tion of heavy cannabis use (Schnell et al. 2009; Yucel et al.
2010). This is supported by the fact that cannabis-using first
episode psychosis (FEP) patients consistently had fewer
neurological soft signs than FEP patients not using cannabis
(Ruiz-Veguilla et al. 2012). The initial neurocognitive per-
formance advantage of this subgroup could be so large that it
would not be neutralized by the putatively subtle cognitive
decline caused by cannabis. Secondly, it has been suggested
that cannabis could improve cognitive functioning by
counteracting a putative neurotoxic process related to schizo-
phrenia or by stimulating prefrontal neurotransmission
(Coulston et al. 2011). Although only adverse consequences
of cannabis use have traditionally been considered in schizo-
phrenia research, the latter hypothesis is not as farfetched as
it may seem because a growing body of evidence indicates
that cannabinoid drugs have a dual neuroprotective–neuro-
toxic profile (Sarne et al. 2011). Furthermore, there is evi-
dence from small-scale clinical studies that some patients
with schizophrenia might benefit from treatment with syn-
thetic Δ-9-tetradhydrocannabinol (Δ-9-THC), the principal
psychoactive constituent of cannabis, as well as cannabidiol,
which is another constituent of cannabis (Leweke et al. 2007;
Schwarcz et al. 2009). However, while several lines of evi-
dence point to a beneficial and even antipsychotic effect of
cannabidiol (Roser et al. 2010), the evidence for a beneficial
effect of THC is much smaller and more controversial.
Moreover, the hypothesis that some patients might experi-
ence neuroprotective- and/or neurocognitive-enhancing ef-
fects of cannabis is difficult to reconcile with results from
prospective observational studies showing that FEP patients
who stopped consuming cannabis have better long-term
functional outcome and fewer negative symptoms compared
to those continuing to consume (Gonzalez-Pinto et al. 2011).
Although a relatively large number of studies have exam-
ined associations between cannabis use and cognitive
performance in schizophrenia patients, most of them have
serious methodological limitations. For instance, several au-
thors have criticized that many studies have not adjusted for
potentially confounding variables, measured only a limited
range of cognitive functions, and used only a single index to
classify cannabis use and this single index was either not
clearly elucidated, was too restricted, and/or tended to be too
broad, and/or did not consider recency of cannabis use
(Coulston et al. 2007b; Segev and Lev-Ran 2012). The latter
seems to be particularly important because the most recent
meta-analysis suggests that the less impaired cognitive per-
formance observed in cannabis-using schizophrenia patients
is mainly driven by the inclusion of lifetime users, rather than
current or recent users (Yucel et al. 2010). A further limita-
tion of previous studies is that they have not examined
whether the associations between cannabis use and neuro-
psychological functioning are stable across different stages
of developing psychoses. Most studies so far have only
included FEP or chronic schizophrenia patients, and only
one study has investigated ARMS patients (Korver et al.
2010).
Hence, the present study for the first time analyzed associa-
tions between cannabis use and cognitive functioning concomi-
tantly in bothARMS and FEP patients. It also improves onmany
of the previous studies by assessing cognitive functioning across
a wide range of domains, by adjusting for the most important
confounders, by including mostly antipsychotic-naïve partici-
pants, and by distinguishing between former, current, and never
users of cannabis. Based on previous findings (Yucel et al. 2010;
Meijer et al. 2012), we hypothesized that less impaired cognitive
functioning would only be present in former users of cannabis,
but not in current users. In addition, we expected that, within the
group of current users, cognitive performance would be worse
with increasing frequency of cannabis use.
Methods
Setting and recruitment
The neuropsychological data analyzed in this study were col-
lected within the prospective Früherkennung von Psychosen
(FePsy) study, which aims to improve the early detection of
psychosis. A more detailed description of the overall study
design can be found elsewhere (Riecher-Rössler et al. 2007,
2009). Participants were recruited into the study via the FePsy
Clinic at the Psychiatric Outpatient Department of the
University Hospital Basel, which was set up specifically to
identify, assess, and treat individuals in the early stages of
psychosis. The study was approved by the ethics committee
of the University of Basel and all participants provided written
informed consent.
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Screening procedure
Screening was performed with the Basel Screening Instrument
for Psychosis (Riecher-Rössler et al. 2008). This instrument
allows the rating of individuals regarding the inclusion/exclusion
criteria corresponding to the PACE criteria (Yung et al. 1998,
2007) and has been shown to have a good interrater reliability
(K=0.67) for the assessment of the main outcome category “at
risk for psychosis” and a high predictive validity (Riecher-
Rössler et al. 2008). Individuals were classified as being in an
ARMS for psychosis, having an FEP, or being not at risk for
psychosis (usually other psychiatric disorders). Only ARMS and
FEP individuals were included in the present study.
Neuropsychological assessment
The neuropsychological test battery was mainly based
on computer-administered tests. All neuropsychological
assessments were conducted by psychologists and well-
trained, supervised advanced students of psychology.
The test battery covered the domains of general intel-
ligence, executive functions, working memory, atten-
tion, verbal learning, and memory (Pflueger et al.
2007; Riecher-Rössler et al. 2009).
The general intelligence was estimated with the
Mehrfachwahl-Wortschatz Test (MWT-A) (Lehrl 1991) and
the Leistungsprüfsystem, scale 3 (Horn 1983). Both are well-
established German intelligence scales for assessing verbal
and nonverbal (abstract reasoning) abilities.
Executive functions were assessed with computer-
administered Tower of Hanoi (Gedika and Schöttke 1994),
Wisconsin Card Sorting Test (Heaton et al. 1993; Drühe-
Wienholt and Wienholt 1998), and Go/No-Go subtest of the
Test for Attentional Performance (Zimmermann and Fimm
1993).
The working memory was measured with the subtest
“Working Memory” of the TAP (Zimmermann and Fimm
1993), the selective attention with the subtest Go/No-Go,
and the vigilance with the Continuous Performance Test
(CPT-OX) (Rosvold et al. 1956).
Verbal learning and memory were assessed with the
California Verbal Learning Test (CVLT) (Delis et al.
1987). To minimize problems associated with multiple
comparisons (i.e., type 1 error inflation), group compar-
isons on CVLT performance were made on the basis of
CVLT composite scores instead of individual measures.
The following three composites were used: auditory
attention, verbal learning, and inaccurate recall. These
composites were derived from a confirmatory factor
analysis model that best fitted the data of a relatively
large sample of epilepsy patients (model 3 in the study
of Banos et al. (2004)).
Psychopathological assessments
The Brief Psychiatric Rating Scale (BPRS) (Lukoff et al.
1986; Ventura et al. 1993) was used to assess positive psy-
chotic symptoms (i.e., hallucinations, suspiciousness, unusu-
al thought content, and conceptual disorganization), and the
Scale for Assessment of Negative Symptoms (SANS)
(Andreasen 1989) was used to assess negative symptoms.
Cannabis use
Cannabis use was assessed with the Basel Interview for
Psychosis (BIP), a semistructured interview that was specifi-
cally developed to obtain medical histories of ARMS and FEP
individuals (Ackermann, master thesis, unpublished; Riecher-
Rössler et al., in preparation). The BIP contains two items
assessing the frequency of past and present cannabis use. Both
items assess the frequency of cannabis use on a five-point
ordinal scale using the following response categories: daily,
several times a week, several times a month, less than several
times a month, and not at all. Whenever cannabis use was
suspected, this was additionally assessed by urine toxicology
screens, i.e., in 53 (41 %) of the included patients. Urine tests
were considered positive when THC-COOH was present in
the urine in a concentration of at least 10 μg/l, in order to infer
a detection window of ≈1 month. Although urine tests were
only available in subset of our sample, the agreement between
urine tests and the questionnaire item on current use was
excellent. That is, all patients with cannabis-positive urine
had responded to the questionnaire item measuring current
cannabis use with a frequency of at least rarely, and all patients
with cannabis-negative urine had responded with a frequency
less than several times per month. Hence, relying only on
information of the BIP in those patients who did not have
urine toxicology screens was considered well justified.
Patients were categorized into three groups: current, for-
mer, and never users. Current users were those that had
cannabis-positive urine or a current cannabis use frequency
of at least several times a month. Former users were required
to have cannabis-negative urine (if available), a past canna-
bis use frequency of at least several times per month, and
current cannabis use of rarely or never. Never users were
required to have cannabis-negative urine (if available) and
past and current cannabis use frequencies of never. Patients
who could not be assigned to one of these categories (e.g.,
because they had consumed cannabis neither regularly nor
never) were excluded.
Statistical analysis
All data were analyzed by using the R environment for
statistical computing (R Development Core Team 2012).
Differences in sociodemographic and clinical characteristics
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between current, former, and never users within each patient
group (i.e., ARMS, FEP, and combined group) were tested
with one-way analysis of variance, Kruskal–Wallis, χ2, or
Fisher’s exact tests.
To investigate the effects of cannabis use (past, former,
and never) and patient group (ARMS and FEP) on
neurocognition, the following procedure was applied. First,
all of the 17 neurocognitive outcome variables were screened
for outliers. Values that were 3 standard deviations above or
below the mean were treated as missing if they could be
attributed to misunderstanding of instructions and truncated
(i.e., replaced by the mean ± 3 standard deviations) if no
obvious cause for their emergence could be found. Because
most of the neurocognitive outcome measures—even after
removal of outliers—did not conform to assumptions of
normality and/or homogeneity of variance, the Box–Cox
transformation (Box and Cox 1964) was applied to each of
these variables. The Box–Cox procedure automatically se-
lected and applied exponential transformations that were
optimal with regard to normalizing distributions and equal-
izing variances (see Supplementary Table 1 for the chosen
transformation of each variable).
Because some of the outcome measures, as well as control
variables, contained considerable proportions of missing
data (see Supplementary Table 1), we next performed multi-
ple imputation (MI) using the Multivariate Imputation by
Chained Equations software (van Buuren and Groothuis-
Oudshoorn 2011). MI is considered the method of choice
of handling complex incomplete data problems because it
yields unbiased parameter estimates and standard errors un-
der a missing at random (MAR) or missing completely at
random (MCAR) missing data mechanism and maximizes
statistical power by using all available information (Enders
2010). Although the MAR or MCAR assumption is not
directly testable (Raykov 2011), it was considered plausible
in the present situation because the variables with the highest
proportion of missing values, such as those of the CVLT,
resulted from changes in the study design over the years and
so the probability of being missing was unlikely to be direct-
ly dependent on the missing values themselves. Furthermore,
even if our data were missing not at random, the MI proce-
dure most likely would have led to less biased results than
the traditional complete case analysis (cf. Enders 2010, on
pages 40, 80, and 344). To estimate the missing values, we
used predictive mean matching and sets of predictors restrict-
ed to those that correlated with at least 0.1 with the variable
to be imputed. To protect against a potential power falloff
from a too small number of imputations (Graham et al.
2007), we generated 100 imputations of the missing values
such that 100 completed datasets were obtained. The analy-
ses of interest (see below) were then conducted in each
completed data set, and parameter estimates were pooled
according to Rubin’s rules (Little and Rubin 1987).
For each neurocognitive outcome variable, an analy-
sis of covariance (ANCOVA) was conducted. Cognitive
functioning was the dependent variable and cannabis
use, patient group, sex, age, premorbid IQ except for
the outcome variable MWT-IQ for which we used years
of education instead of premorbid IQ, and the cannabis
use × patient group interaction were independent vari-
ables. If the cannabis use × patient group interaction
was not significant, it was removed from the final
models.
To investigate whether neurocognition was associated
with the frequency of cannabis use, additional
ANCOVAs were fitted for each neurocognitive outcome
variables based on the group of current cannabis users
only and using the frequency of current cannabis use,
patient group, sex, age, premorbid IQ except for the
outcome variable MWT-IQ for which we used years of
education instead of premorbid IQ, and cannabis fre-
quency × patient group as independent variables.
Again, if the cannabis frequency × patient group interaction
was not significant, it was removed from the final models. The
analysis was restricted to current cannabis use because it was
less likely to be subject to recollection bias than past cannabis
use. Furthermore, the effects of cannabis were less likely to be
confounded by the time that has elapsed since its last use,
which could be up to 10 years in some cases.
Results
Sample description
One hundred twenty-six ARMS individuals and 98 FEP
patients were recruited into the FePsy study from March
1, 2000 to April 1, 2013. Of these, 18 ARMS and 13
FEP patients were excluded because they did not have
any cognitive performance measures. In the remaining
sample, three ARMS and eight FEP patients were ex-
cluded because they had used cocaine, MDMA, opiates,
hallucinogens, or amphetamines at least several times
per week at some time in their lives. Finally, 31
ARMS and 15 FEP patients were excluded because they
had neither consumed cannabis regularly nor never and
therefore could not be assigned to one of the three
cannabis groups. Analyses were performed on the
remaining sample, which consisted of 136 participants
(74 ARMS and 62 FEP patients). The 88 individuals
that were excluded from this study did not differ from
the included individuals with regard to gender, sex,
years of education, patient group and BPRS total and
positive symptoms scores. Sociodemographic and clini-
cal characteristics as well as frequencies of cannabis use
of the included individuals are presented in Table 1.
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Within the total and ARMS groups, cannabis groups
(i.e., current, former, and never users) were significantly
different with regard to age. Pairwise comparisons re-
vealed that this was because never users were signifi-
cantly older than former users within both the total
(p=0.022) and ARMS (p=0.033) groups. There were
no significant differences between current, former, and
never users of cannabis with regard to gender, years of
education, age at onset of cannabis use, BPRS positive
symptoms, BPRS total score, SANS total score, and use
of antipsychotics, tranquilizers, and antidepressives nei-
ther within the total group nor within the FEP or
ARMS subgroups. Almost all ARMS individuals were
antipsychotic naïve; only three ARMS individuals (3/70)
had received low doses of second-generation antipsy-
chotic medication during no more than 3 weeks for
behavioral control by the referring psychiatrist or gen-
eral practitioner prior to study inclusion. Also, the major-
ity of the FEP patients (33/56) were antipsychotic naïve.
Effects of cannabis use and patient group on cognitive
functioning
In the ANCOVA models that included recency of can-
nabis use (current, former, and never use) and patient
group (ARMS vs. FEP) as between subject factors and
sex, age, premorbid IQ except for the outcome variable
MWT-IQ for which we used years of education instead
of premorbid IQ, and use of antipsychotics as covari-
ates, there were no significant interaction effects be-
tween recency of cannabis use and patient group on
any cognitive performance measure. The main effect of
recency of cannabis use (former, past, and never use)
was only significant for the dependent variable Go/No-
Go omissions. Inspections of the regression coefficients
of the two dummy variables formed from the categorical
variable recency of cannabis use indicated that this was
because both former and current users had fewer omis-
sions than never users. However, these differences were
no longer significant when p values were corrected for
multiple testing by the Benjamini–Hochberg method
(Benjamini and Hochberg 1995). Figure 1 displays the
performance differences of current and former users
compared to never users on all analyzed cognitive per-
formance measures in the total group. Supplementary
Table 2 provides effect sizes (Cohen’s d), confidence
intervals, test statistics, and p values of the cannabis
group differences in the total group. Supplementary
Figs. 1 and 2 and supplementary Tables 3 and 4 report
about the same differences separately for ARMS and
FEP patients.
As shown in Fig. 2, FEP patients tended to have lower
cognitive performance than ARMS individuals on mostT
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cognitive measures. However, the differences between these
two groups were only statistical trends for the number of
omissions in the Go/No-Go task (p=0.071) and for the
number of omissions in the CPT task (p=0.069).
Cannabis frequency and cognitive functioning
In the analyses restricted to current users, the interaction be-
tween patient group and cannabis frequency (daily, weekly, and
Fig. 2 Cognitive performance of first episode psychosis (FEP) patients
compared to at-risk mental state (ARMS) patients. The dotted horizon-
tal line at zero represents the performance of ARMS patients. Differ-
ences are expressed in units of Cohen’s d and are significant if the 95 %
confidence interval (vertical line) does not overlap with zero. Variables
with a minus sign were reversed such that high scores always represent
good performance. Differences are adjusted for the influence of canna-
bis group, sex, age, and premorbid IQ and antipsychotics except for the
outcome variable MWT-IQ for which we used years of education
instead of premorbid IQ
Fig. 1 Cognitive performance of current and former cannabis users
compared to never users within the combined group of at-risk mental
state (ARMS) and first episode psychosis (FEP) patients. The dotted
horizontal line at zero represents the performance of never users.
Differences are expressed in units of Cohen’s d and are significant if
the 95 % confidence interval (vertical line) does not overlap with zero.
Variables with a minus sign were reversed such that high scores always
represent good performance. Differences are adjusted for the influence
of patient group, sex, age, and premorbid IQ and antipsychotics except
for the outcome variable MWT-IQ for which we used years of educa-
tion instead of premorbid IQ
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less than weekly use of cannabis) was not statistically signifi-
cant for any of the cognitive performance measures, as can be
seen in Fig. 3. Supplementary Table 5 provides effect sizes
(Cohen’s d), confidence intervals, test statistics, and p values of
these differences in the total group. Supplementary Figs 3 and 4
and supplementary Tables 6 and 7 report about the same
differences separately for ARMS and FEP patients.
Discussion
In this study, we examined for the first time the effects
of cannabis use on neuropsychological performance in a
combined sample of FEP and ARMS participants. We
hypothesized that—compared to never users of
cannabis—less impaired cognitive functioning would
only be present in former users, but not in current users
of cannabis and that, within the group of current users,
high cannabis use frequency would be associated with
worse cognitive performance. Both hypotheses were not
confirmed in the present study. Except for a small
significant difference in the number of omissions during
Go/No-Go trials, which did not withstand correction for
multiple testing, there were no cognitive performance
differences between former, current, and never users of
cannabis. Furthermore, we did not find worse cognitive
performance with increased cannabis use frequency
within the group of current users.
The rejection of the first hypothesis in the present study
stands in contrast to the four most recent meta-analyses
(Potvin et al. 2008; Loberg and Hugdahl 2009; Yucel et al.
2010; Rabin et al. 2011), which found less impaired cognitive
functioning in schizophrenia patients with a history of canna-
bis use, and to several studies indicating that this difference
might be due to the inclusion of former users (Yucel et al.
2010; Meijer et al. 2012). There are multiple possible reasons
for these discrepancies: First, while most of the studies defined
the group of cannabis users according to diagnostic criteria of
cannabis abuse or dependence using Structured Clinical
Interview (SCID) for DSM-IV (Coulston et al. 2007a), we
assessed cannabis use with a semistructured interview and by
urine toxicology screens. The use of the SCID criteria might
have led to the inclusion of more heavy users than in our
study. Furthermore, in other studies, the cannabis-naïve group
was often defined by the absence of a DSM-IV cannabis use
disorder, which, unlike in our study, might have led to the
inclusion of occasional cannabis users or more frequent and
heavy users whose functioning is unaffected to the extent in
which a substance use disorder diagnosis is made.
Second, the discrepancy between our and other studies
might be due to differences in neuropsychological test bat-
teries. For instance, some of the neuropsychological perfor-
mance measures, such as the number of omissions in the
Go/No-Go and working memory task, were subject to strong
floor effects (i.e., a relatively large number of subjects had
zero omissions). Thus, it is possible that these measures did
Fig. 3 Cognitive performance of weekly and daily current cannabis
users compared to current cannabis users using cannabis less than
weekly within the combined group of at-risk mental state (ARMS)
and first episode psychosis (FEP) patients. The dotted horizontal line
at zero represents the performance of current cannabis users using
cannabis less than weekly. Differences are expressed in units of Cohen’s
d and are significant if the 95 % confidence interval (vertical line) does
not overlap with zero. Variables with a minus sign were reversed such
that high scores always represent good performance. Differences are
adjusted for the influence of patient group, sex, age, and premorbid IQ
and antipsychotics except for the outcome variable MWT-IQ for which
we used years of education instead of premorbid IQ
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not differentiate enough between groups with different cog-
nitive functioning. On the other hand, we did not find dif-
ferences in the cognitive measures that were not subject to
floor or ceiling effects either.
Finally, we might have obtained different results because
our participants consumed cannabis with different potency
and cannabinoid ratios than in other studies. A growing
number of studies suggest that THC and cannabidiol, which
are both contained in cannabis products with varying concen-
tration, have opposite effects on cognition (Bhattacharyya
et al. 2010). Data suggest diverging trends across Europe in
the mean level of THC of cannabis in recent years, with a
decrease or stabilization in some countries and an increase in
other countries (King 2008).
The rejection of our second hypothesis is in line with other
studies, which also did not find schizophrenia patients who
used cannabis daily or weekly performing significantly worse
than participants with less frequent use of cannabis (Rodriguez-
Sanchez et al. 2010; Meijer et al. 2012). Although this seems
counterintuitive, one explanation might be that daily and week-
ly users of cannabis to some extent became tolerant to the
negative effects of cannabis. Meijer et al. (2012), who also
did not find a dose–response effect, speculated that the classi-
fication of frequency in daily, weekly, and monthly use might
not be sensitive enough to detect cognitive differences.
The following limitations should be taken into account:
We did not assess the duration, quantities of cannabis use,
concentration of cannabidiol and THC, and maximum fre-
quency of use over the lifetime. Consequently, we could not
control for these influences. Furthermore, the moderate sam-
ple size of the present study precluded the detection of small
effects. This could be particularly problematic because some
studies indicate that cognitive performance differences be-
tween cannabis use groups are quite small (Meijer et al.
2012). However, we also did not find statistical trends for
differences in cognitive functioning in most variables even
without correction for multiple testing. Furthermore, the sign
of the differences between groups was quite heterogeneous.
Moreover, Yucel et al. (2010) found in their meta-analysis
that the difference between lifetime/past cannabis users with
never users on global cognition has an average effect size of
Cohen’s d=0.55. If we take this as an estimate of the popu-
lation effect size and calculate power based on a two sample t
test with group sizes equal to our study, a significance level
of 0.05, and a two-tailed hypothesis test, we get an estimated
power of 0.7 for testing the main effect of interest in our
study. Hence, we consider it rather unlikely that our hypoth-
eses were mainly rejected due to insufficient statistical pow-
er. It should also be noted that, although our sample size was
moderate, it was still larger than in most previous studies (cf.,
Rabin et al. 2011).
In conclusion, the results of the present study do not
support the notion that FEP and ARMS participants with a
history of cannabis use have less impaired cognitive func-
tioning. We also found no evidence that the less impaired
cognitive functioning in cannabis-using FEP patients, which
has been reported in some previous studies, is due to the
inclusion of former users or that associations between can-
nabis use and cognitive functioning differ between ARMS
and FEP patients.
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